TTK Healthcare Limited (TTKHLTCARE)

Diversified · Diversified · NSE · Updated 15 July 2026

₹995.3 ↓ 26.58% (1Y)

🎯 Key Takeaways

TTK Healthcare Limited is in a mature, cash-generating phase with signs of stabilization after a period of volatility. The company has demonstrated consistent profitability and governance discipline, with a focus on strategic reinvestment and shareholder returns.
⚠️ Margin pressure from input cost volatility in raw materials and manufacturing was explicitly flagged in the annual report, posing a near-term headwind

Market Cap

₹1,268

P/E Ratio

21.1

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About TTKHLTCARE 📊 Interactive Charts

📖 The Story

TTK Healthcare Limited is in a mature, cash-generating phase with signs of stabilization after a period of volatility. The company has demonstrated consistent profitability and governance discipline, with a focus on strategic reinvestment and shareholder returns. Management is emphasizing long-term growth in medical devices and pet care while navigating macroeconomic headwinds. The business remains fundamentally sound but operates in a constrained growth environment.

📰 What's Happening

In the last two quarters, TTK Healthcare has focused on governance and shareholder resolutions ahead of its FY2025-26 AGM scheduled for July 24, 2026. Key developments include the reappointment of Executive Chairman T T Raghunathan for five years, the declaration of a dividend of Rs.10 per share (100% payout), and approval of cost auditor remuneration. The company also filed its annual report and BRSR on June 27, 2026, reaffirming its strategic focus on medical devices, animal welfare, and pleasure products. A trading window closure was announced for designated persons ahead of Q1 FY2027 results, signaling upcoming board-level scrutiny. No major acquisitions or capital raises were disclosed.

Source: Stock Announcements

🔮 Management Outlook & What's Next

Management has expressed confidence in long-term growth through expansion in medical devices and export markets, particularly within Ayushman Bharat and international healthcare channels. The reappointment of the Executive Chairman for five years underscores leadership continuity. While no formal revenue or earnings guidance was provided, management highlighted opportunities in product innovation and segmental diversification. The focus remains on sustainable profitability, capital efficiency, and stakeholder engagement, with execution tied to upcoming product launches and market penetration strategies.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Diversified

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Godrej Industries Limited	38,229	27.0	—	—	—
3M India Limited	35,198	57.6	38.4%	28.5%	0.00
DCM Shriram Limited	17,578	32.4	—	—	—
Kama Holdings Limited	8,456	—	—	—	—
Balmer Lawrie & Company Limited	3,327	12.6	—	—	—
TTK Healthcare Limited	1,268	21.1	—	—	—
Gillanders Arbuthnot & Company Limited	201	9400.0	—	—	—
Aspinwall and Company Limited	183	10.2	—	—	—

🔗 Peer Stock Analyses

GODREJIND 3MINDIA DCMSHRIRAM KAMAHOLD BALMLAWRIE

⚠️ Risk Factors

1. Margin pressure from input cost volatility in raw materials and manufacturing was explicitly flagged in the annual report, posing a near-term headwind. 2. Geopolitical instability could disrupt export growth plans in healthcare and medical devices, particularly in emerging markets. 3. The company's diversification into pet care and pleasure products introduces execution risk due to niche market dynamics and regulatory uncertainty. 4. Despite stable governance, the lack of forward-looking financial guidance limits predictability for investors seeking near-term earnings visibility.

📋 Recent Filings

🧠 Analyst's Read

TTK Healthcare presents as a stable, dividend-paying entity with improving governance and consistent profitability, but its growth trajectory remains modest and execution-dependent. Investors should monitor the successful commercialization of medical device and pet care initiatives, as well as margin resilience amid input cost pressures. The upcoming AGM and potential updates on strategic investments will be critical catalysts for re-rating the stock.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on TTKHLTCARE

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-15.

📡 Get AI alerts when TTKHLTCARE files new disclosures

Track TTKHLTCARE filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track TTKHLTCARE — Free

Free account · 2 AI queries/day